MPM BioVentures 2014, L.P. Offloads 259,837 Shares of Entrada Therapeutics (NASDAQ: TRDA) at $7.11-$7.41 Each
MPM BioVentures 2014, L.P. sold 259,837 shares of Entrada Therapeutics (NASDAQ: TRDA) between September 4 and September 9, 2026, at prices ranging from $7.11 to $7.41 per share. Following these transactions, the insider's reported ownership stands at 3,885,115 shares. These sales were executed as open-market transactions, and MPM BioVentures 2018, L.P. is also noted as an insider.
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
Entrada Therapeutics has announced the recipients of its 2026 DREAMS Grant Program, awarding two $50,000 grants to Parent Project Muscular Dystrophy (PPMD) in the U.S. and Duchenne Parent Project Netherlands. These grants support projects aimed at bridging healthcare disparities within the global Duchenne muscular dystrophy community. The initiatives will focus on improving access to specialized care for underserved populations, particularly adults and those in rural areas, and promoting autonomy and social participation for individuals transitioning into adulthood.
Entrada therapeutics 10% owner MPM BioVentures sells $1.9M stock
MPM BioVentures 2014, L.P., a 10% owner of Entrada Therapeutics (NASDAQ:TRDA), sold approximately $1.91 million worth of common stock in early September 2026. The sales occurred over three trading days with weighted average prices between $7.11 and $7.41 per share, amidst operational challenges for Entrada, including rapid cash burn and an anticipated revenue decline. Despite the sales, InvestingPro analysis suggests the shares are undervalued with a Fair Value of $7.91.
MPM funds sell 259,837 Entrada Therapeutics (TRDA) shares over 3 days
Investment funds affiliated with MPM BioVentures, identified as ten percent owners of Entrada Therapeutics, Inc. (TRDA), indirectly sold a total of 259,837 shares of Common Stock over three days in September 2026. The sales occurred at weighted average prices ranging from approximately $7.01 to $7.70 per share. Following these transactions, the MPM entities reported remaining holdings across various partnerships and LLCs.
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com
MPM BioVentures 2018, a significant shareholder and director of Entrada Therapeutics, recently sold approximately $1.91 million worth of the company's common stock across three separate transactions in early September 2026. The sales occurred while TRDA shares were trading around $7.11, following a 31% year-to-date decline but a 36% gain over the past year. Following these transactions, MPM BioVentures 2018 and its affiliated entities indirectly retain ownership of over 3.8 million shares.
MPM funds sell Entrada (TRDA) shares, still hold stakes over 1.7M each
Funds affiliated with MPM BioVentures, which are ten percent owners of Entrada Therapeutics (TRDA), recently sold a total of 259,837 shares in several open-market transactions between September 4 and September 9, 2026. Despite these sales, the funds retain substantial holdings, with MPM BioVentures 2014, L.P. holding 1,764,167 shares and MPM BioVentures 2018, L.P. holding 1,810,592 shares. The sales occurred at weighted average prices ranging from $7.11 to $7.41 per share, and no Rule 10b5-1 trading plan was reported.
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares
MPM BioVentures 2018, L.P. and its affiliates, a significant owner of Entrada Therapeutics Inc. (NASDAQ:TRDA), recently sold approximately $1.91 million worth of company shares in early September 2026. The sales occurred across three transactions with weighted average prices ranging from $7.11 to $7.41 per share, while Entrada's stock trades at $7.11, down 31% year-to-date but up 36% over the past year. Despite the sales, InvestingPro analysts suggest Entrada is undervalued, with price targets between $11 and $25.
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com
MPM BioVentures, a 10% owner and director of Entrada Therapeutics Inc. (NASDAQ:TRDA), sold common stock worth $617,378 between September 1 and September 3, 2026. A total of 86,482 shares were sold at weighted average prices ranging from $7.06 to $7.19. Following these transactions, MPM BioVentures and its affiliates still beneficially own 4,144,952 shares of Entrada Therapeutics.
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics
MPM BioVentures, a 10% owner of Entrada Therapeutics, Inc. (NASDAQ:TRDA), sold 86,482 shares of common stock for a total of $617,378 between September 1 and September 3, 2026. The sales were made at weighted average prices ranging from $7.06 to $7.19. Following these transactions, MPM BioVentures and its affiliates beneficially own 4,144,952 shares of Entrada Therapeutics.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics announced the grant of inducement stock options to five new employees. These grants, totaling 74,400 shares of common stock, were made outside the company's 2021 Equity Incentive Plan but conform to Nasdaq Listing Rule 5635(c)(4). The options vest over four years, subject to continued employment, and have an exercise price equal to the closing price on the grant date.
Institutional holder sells Entrada (NASDAQ: TRDA) shares over three days
MPM-affiliated entities, identified as ten percent owners of Entrada Therapeutics (NASDAQ: TRDA), sold a total of 86,482 common shares over three days in early September 2026. The sales occurred between September 1-3, 2026, with weighted average prices ranging from approximately $7.06 to $7.19 per share. These transactions were indirect sales across several MPM limited partnerships and LLCs, and no Rule 10b5-1 trading plan was reported.
Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock
MPM BioVentures 2014 L.P., a significant owner of Entrada Therapeutics (TRDA), sold 86,914 shares totaling $615,777 in late August 2026, despite analysts maintaining a "strong buy" consensus for the stock. The sales occurred across three transactions as the stock traded at $7.05, down 31% year-to-date, though InvestingPro analysis suggests it remains undervalued. Concurrently, Entrada Therapeutics received approval to proceed with a higher dose in its Duchenne Muscular Dystrophy study, marking a positive development in its research efforts.
Mpm Bioventures 2018 sells $615,777 in Entrada Therapeutics stock By Investing.com
MPM BioVentures 2018, L.P., a major shareholder in Entrada Therapeutics (NASDAQ:TRDA), sold $615,777 worth of common stock between August 27 and August 31, 2026, at prices ranging from $6.99 to $7.2 per share. Following these transactions, the entity and its affiliates indirectly hold 4,231,434 shares. Despite the sales, analysts view the stock as undervalued, with price targets between $11 and $25, and the company recently received clearance to escalate the dose in its Duchenne muscular dystrophy drug trial.
Mpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock
MPM BioVentures 2018, a significant shareholder in Entrada Therapeutics (NASDAQ:TRDA), recently sold shares worth $461,545 over three days, with prices ranging from $7.06 to $7.54. These sales occurred as the stock experienced an 8% decline for the week, despite InvestingPro analysis suggesting it is undervalued with a fair value of $7.95. Concurrently, Entrada Therapeutics received approval to increase the dosage in its Duchenne muscular dystrophy study, marking a positive clinical development.
Mpm Bioventures sells $461,545 in Entrada Therapeutics stock By Investing.com
MPM BioVentures 2014, L.P., a 10% owner and director of Entrada Therapeutics Inc. (NASDAQ:TRDA), sold a total of $461,545 worth of common stock over three days in late August 2026. The sales occurred at weighted average prices between $7.06 and $7.54 per share. Despite these sales, analysts maintain a consensus Buy rating on Entrada Therapeutics, with price targets ranging from $11 to $25.
Mpm Bioventures sells $461,545 in Entrada Therapeutics stock
MPM BioVentures 2014, L.P., a significant shareholder and director of Entrada Therapeutics Inc. (NASDAQ:TRDA), sold $461,545 worth of common stock in late August 2026 across three separate transactions. The sales occurred at weighted average prices between $7.06 and $7.54 per share, leaving MPM BioVentures 2014, L.P. with 4,318,348 shares indirectly. The biotech company, with a market cap of $252 million, faces financial challenges despite analysts maintaining a consensus "Buy" rating.
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
Entrada Therapeutics (TRDA) shares recently surged by 8.9%, closing at $15.79, driven by investor optimism regarding its product pipeline and upcoming clinical milestones for RNA-based therapies. The company is advancing several candidates for neuromuscular diseases, with key data readouts and clinical milestones anticipated in 2026. Despite a projected quarterly loss and revenue decline, the stock currently holds a Zacks Rank #3 (Hold).
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Entrada Therapeutics Inc (TRDA) has an earnings forecast score of 8.50 and is ranked 109th in the Biotechnology & Medical Research industry. Analysts project a target price of $16.50 for TRDA, with an expected revenue of $5.26M for the next quarter. Most analysts recommend a "Buy" for Entrada Therapeutics Inc, though investors should conduct their own research.
HC Wainwright Analysts Lower Earnings Estimates for TRDA
HC Wainwright analysts have reduced their Q3 2026 earnings per share estimates for Entrada Therapeutics (NASDAQ:TRDA) to a loss of $1.18, maintaining a "Neutral" rating. The company's recent quarterly results missed expectations, reporting a $1.01 loss per share against an anticipated $0.97 loss, and revenue of $0.90 million versus a $2.32 million consensus. Despite high institutional ownership, analyst sentiment remains mixed with a consensus "Hold" rating and a target price of $17.50, significantly higher than its recent trading price of $7.04.
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $73,458.00 in Stock
Entrada Therapeutics (NASDAQ:TRDA) Director Kush Parmar sold 10,494 shares of the company's stock for $73,458, reducing his stake by 0.37%. This sale is part of several recent transactions by Parmar. The company's stock traded up 1.2% to $6.95, despite missing analyst estimates for its quarterly earnings and revenue.
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock
5am Ventures V, L.P. sold $431,829 worth of Entrada Therapeutics Inc. stock through multiple transactions on August 6 and 7, 2026. The sales occurred at prices ranging from $6.85 to $7.0 per share. Despite a 32% year-to-date decline and trading 58% below its 52-week high, InvestingPro analysis suggests the company is undervalued, though it is quickly burning through cash.
5AM Ventures V reports Entrada Therapeutics share disposal worth $431,620
5AM Ventures V sold 62,811 common shares of Entrada Therapeutics on August 6-7, 2026, for a total value of $431,620. Following these sales, their direct stake in the company decreased to 2,783,781 shares, while 5AM Opportunities I held an indirect stake of 1,093,313 shares.
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock By Investing.com
5am Ventures V, L.P., a significant owner of Entrada Therapeutics, Inc. (NASDAQ:TRDA), sold common stock worth $431,829 across multiple transactions on August 6 and 7, 2026, at prices between $6.85 and $7.0 per share. Despite a 32% year-to-date decline in the stock, InvestingPro analysis indicates it may be undervalued, though the company is rapidly burning through cash. Entrada Therapeutics also received clearance to proceed with a higher dose in its ELEVATE-45-201 study, marking a key development in its clinical programs.
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $358,371.45 in Stock
Entrada Therapeutics (NASDAQ:TRDA) Director Kush Parmar sold 52,317 shares of the company's stock for $358,371.45 on August 7th, reducing his ownership by 1.84%. This sale is part of a series of recent transactions by Parmar, totaling significant amounts in August and July. The company's stock is trading near $6.95, and it recently reported a quarterly loss and missed revenue expectations, leading analysts to hold an average "Hold" rating with a target price of $17.50.
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock By Investing.com
5am Ventures V, L.P., a major stakeholder in Entrada Therapeutics Inc. (NASDAQ:TRDA), sold $431,829 worth of common stock across multiple transactions on August 6 and 7, 2026, with prices ranging from $6.85 to $7.00 per share. Despite the stock's year-to-date decline, InvestingPro analysis suggests it remains undervalued, though the company is rapidly burning cash. Separately, Entrada Therapeutics received clearance to proceed with a higher dose in its ELEVATE-45-201 study, marking a significant step in its clinical programs.
5AM Ventures V reports Entrada Therapeutics share disposal worth $431,620
5AM Ventures V has reported the sale of 62,811 Entrada Therapeutics common shares between August 6-7, at weighted-average prices of $7 and $6.85, totaling approximately $431,620. Following these transactions, their direct stake in Entrada Therapeutics decreased to 2,783,781 shares. An indirect stake of 1,093,313 shares is held by 5AM Opportunities I.
Entrada Therapeutics (TRDA): 5AM Ventures-linked funds sell 62,811 shares, retain over 1.09M
Investment funds associated with 5AM Ventures, a major stockholder in Entrada Therapeutics (TRDA), sold a total of 62,811 shares of common stock on August 6-7, 2026. The sales were executed at weighted average prices of $7.00 and $6.85 per share. Following these transactions, an affiliated fund, 5AM Opportunities I, L.P., still holds 1,093,313 shares of Entrada Therapeutics common stock indirectly.
Entrada Therapeutics, Inc. (TRDA) stock price, news, quote and history
This page provides comprehensive information on Entrada Therapeutics, Inc. (TRDA), including its current stock price, trading activity, historical data, and company profile. It details the company's financials, performance overview against the S&P 500, earnings trends, and analyst ratings, offering a complete snapshot for investors. The article also lists similar companies for comparison and highlights trending tickers.
Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA)
This article highlights two healthcare stocks, Insulet (PODD) and Entrada Therapeutics Inc (TRDA), which have received bullish sentiments from analysts. Steven Lichtman of William Blair maintained a Buy rating on Insulet, while Myles Minter, also from William Blair, maintained a Buy rating on Entrada Therapeutics Inc. Both companies show significant upside potential according to analyst consensus.
Entrada Therapeutics, Inc. (TRDA) Stock Price, News, Quote & History
This page provides comprehensive financial data for Entrada Therapeutics, Inc. (TRDA), a clinical-stage biopharmaceutical company. It includes real-time stock price, historical data, key statistics, performance overview against the S&P 500, earnings trends, analyst insights, and valuation measures. The company focuses on developing genetic medicines for neuromuscular and inherited retinal diseases using its Endosomal Escape Vehicle technology.
Entrada Therapeutics Releases Q2 2026 Financial Results
Entrada Therapeutics, Inc. reported a net loss of $42.8 million for the first half of 2026, reflecting continued investment in its pipeline of intracellular therapeutics. The company posted a loss of $1.01 per share, with revenue totaling $898,000, a 54.0% decrease from H1 2025. These results highlight the capital-intensive nature of advancing therapeutic candidates through clinical development as a pre-commercial biotech firm.
Entrada Therapeutics, Inc. (TRDA) stock price, news, quote and history
This article provides a comprehensive overview of Entrada Therapeutics, Inc. (TRDA), a clinical-stage biopharmaceutical company. It covers the company's stock performance, key financial metrics, recent news, analyst ratings, and a description of its focus on developing new medicines for neuromuscular and inherited retinal diseases. The company's stock closed at $6.87, with pre-market activity showing a rise to $7.09.
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Entrada Therapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The brief report indicates the company's financial performance for the specified period. The full details are available through Refinitiv and other news sources on TradingView.
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
Entrada Therapeutics announced its second-quarter 2026 financial results, highlighted by upcoming clinical data readouts for its Duchenne muscular dystrophy (DMD) programs and progress in its myotonic dystrophy type 1 (DM1) partnership with Vertex. The company reported a cash position of $223.0 million, sufficient to fund operations into the third quarter of 2027, and a net loss of $42.8 million for the quarter. Multiple data readouts are anticipated throughout late 2026 and early 2027 for its ELEVATE-44-201 and ELEVATE-45-201 studies, alongside continued advancement of its preclinical pipeline in ocular and metabolic diseases.
Entrada Therapeutics (NASDAQ: TRDA) details $82M H1 loss and $223M cash runway
Entrada Therapeutics reported a net loss of $42.8 million for Q2 2026 and $82.5 million for the first half of 2026, with collaboration revenue declining due to the completion of major research milestones. The company maintains a strong cash position of $223.0 million, expected to fund operations into Q3 2027. Entrada also highlighted positive clinical data from its ELEVATE-44-201 trial for Duchenne muscular dystrophy, showing dystrophin increases and functional improvements, and provided updates on other pipeline programs.
Entrada Therapeutics publishes corporate presentation on genetic medicines pipeline for neuromuscular and inherited retinal diseases
Entrada Therapeutics announced upcoming clinical data catalysts for 2026 across Duchenne muscular dystrophy and myotonic dystrophy type 1. The company's ENTR-601-44 Phase 1/2 Cohort 1 showed significant improvement in Time to Rise and no serious adverse events. Future data releases include Cohort 1 open-label function and safety data by year-end 2026, Cohort 2 data in Q1 2027, and Vertex's VX-670 data in H2 2026.
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) reported a narrower-than-expected Q2 loss of $1.01 per share, beating the Zacks Consensus Estimate of a $1.16 loss. The company also surpassed revenue estimates, posting $0.9 million for the quarter, although this was lower than the $1.95 million reported a year ago. Despite outperforming EPS estimates in three of the last four quarters, TRDA shares have decreased by nearly 30% year-to-date.
Entrada Therapeutics (Nasdaq: TRDA) reports Q2 2026 results and sets DMD, DM1 data timeline
Entrada Therapeutics (TRDA) reported a Q2 2026 net loss of $42.8 million and outlined upcoming clinical milestones for its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs. The company held $223.0 million in cash, expected to fund operations into Q3 2027, and anticipates multiple data readouts between late 2026 and mid-2027 for its ELEVATE studies and the VX-670 collaboration with Vertex.
Entrada Therapeutics, Inc. 2026: Revenue $898K, EPS ($1.01) — 10-Q Summary
Entrada Therapeutics, Inc. reported its Q2 2026 results, showing collaboration revenue of $898K and a diluted loss per share of ($1.01). The company highlighted clinical advancements in its DMD programs, progress in its collaboration with Vertex, and an expected funding runway into Q3 2027 with $223M in cash resources.
Entrada Therapeutics reports Q2 2026 results: $223.0M cash; Q2 net loss $42.8M
Entrada Therapeutics reported its second-quarter 2026 financial results, showing a net loss of $42.8 million and cash, cash equivalents, and marketable securities totaling $223.0 million. The company expects its cash reserves to fund operations into Q3 2027. Entrada also provided updates on its clinical programs, including progress in its ELEVATE-44-201 and ELEVATE-45-201 studies, regulatory advancements for ENTR-601-50 and ENTR-601-51, and developments in its collaboration with Vertex Pharmaceuticals.
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
Entrada Therapeutics reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) clinical programs. The company anticipates several key data readouts in late 2026 and early 2027 for its ELEVATE-44-201 and ELEVATE-45-201 studies, as well as data from its collaboration with Vertex on VX-670 for DM1. Entrada Therapeutics maintains a strong cash position expected to fund operations into Q3 2027.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Recommendation of "Hold" from Brokerages
Entrada Therapeutics, Inc. (NASDAQ:TRDA) has received an average "Hold" recommendation from brokerages, based on a mix of sell, hold, and buy ratings, with an average 12-month price target of $17.50. The company's shares opened at $7.26 and have traded between $4.93 and $16.45 over the past year. Despite beating EPS expectations, Entrada's revenue fell short of consensus estimates, and insiders have sold shares while institutional investors maintain a significant stake.
5am Ventures V sells $807,027 of Entrada Therapeutics stock
5am Ventures V, a significant owner and director of Entrada Therapeutics (NASDAQ:TRDA), recently sold shares worth $807,027. These transactions occurred on July 30 and July 31, 2026, with share prices ranging from $6.85 to $6.93, even though TRDA stock has recently surged by 24.5%. The company is also progressing with its Duchenne Muscular Dystrophy study and plans to release topline results from another clinical study soon.
Entrada Therapeutics director, 10% owner Kush Parmar disposes of $807,529 in common shares
Entrada Therapeutics director and 10% owner Kush Parmar sold 116,474 common shares on July 30-31, totaling $807,529. These transactions reduced 5AM Ventures V's stake to 2,846,592 shares, while 5AM Opportunities I held 1,093,313 shares afterward. This news brief was generated by AI based on information from the U.S. SEC's EDGAR system.
Entrada Therapeutics director Kush Parmar sells $807,027 in shares
Kush Parmar, a director and 10% owner of Entrada Therapeutics (NASDAQ:TRDA), recently sold $807,027 worth of company shares through 5AM Ventures V, L.P., across two transactions on July 30 and 31, 2026. The sales occurred as TRDA stock surged 24.53% over the past week and traded above its InvestingPro Fair Value estimate. The company also recently received clearance to escalate dosage in its ELEVATE-45-201 study and is set to report topline results for its ENTR-601-44 clinical study soon.
5am Ventures V sells $807,027 of Entrada Therapeutics stock
5AM Ventures V, L.P., a significant owner and director of Entrada Therapeutics (NASDAQ:TRDA), recently sold shares worth $807,027. These transactions occurred over two days, with shares sold at prices between $6.85 and $6.93, even as the stock has surged 24.5% in the past week to $7.26. The company is also progressing with its Duchenne Muscular Dystrophy study and is expected to release topline results from another clinical study soon.
Form 4 Entrada Therapeutics Inc For: 4 August By Investing.com
This article from Investing.com is a minimal announcement regarding a Form 4 filing for Entrada Therapeutics Inc, dated August 4. It provides the stock symbol TRDA and notes a -2.20% change. The content primarily consists of navigation, advertisements, and market data rather than detailed information about the Form 4 filing itself.
Entrada Therapeutics (TRDA) holder sells shares, still reports 1.09M stake
5AM Ventures V, L.P., a ten percent shareholder of Entrada Therapeutics (TRDA), reported selling a total of 116,474 shares of common stock on July 30-31, 2026, with transactions occurring at a weighted average price of $6.93 per share. Despite these sales, affiliated entity 5AM Opportunities I, L.P. still indirectly holds 1,093,313 shares of Entrada Therapeutics as of July 30, 2026. The transaction details were disclosed in a Form 4 SEC filing, which also identifies other related reporting persons and clarifies beneficial ownership.
Entrada Therapeutics Insider Sold Shares Worth $807,027, According to a Recent SEC Filing
Kush Parmar, a 10% Owner and Director at Entrada Therapeutics (TRDA), sold 116,474 shares of the company's stock on July 30, 2026, for a total value of $807,027. This transaction was disclosed in a recent SEC filing. Further details about this premium news article require a subscription to Yahoo Finance Gold.
Liquidity Mapping Around (TRDA) Price Events
This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA) using AI models, highlighting a positive near-term sentiment within a long-term strength context despite a mid-term weak bias. It identifies key support and resistance levels and outlines three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also points to an exceptional 171.0:1 risk-reward setup targeting a 51.4% gain.
